Literature DB >> 8807689

A comparison of two levels of family-aided assertive community treatment.

W R McFarlane1, R A Dushay, P Stastny, S M Deakins, B Link.   

Abstract

OBJECTIVE: The study examined differences in outcomes for patients with schizophrenic disorders who were receiving assertive community treatment based on whether their families were involved in their treatment more intensively in psychoeducational multifamily groups or episodically in crisis family intervention.
METHODS: Sixty-eight individuals who met DSM-III-R criteria for schizophrenic disorders and who had at least one other major complicating factor were randomly assigned to the two treatment conditions, and clinical and functional outcomes over a 24-month follow-up period were compared.
RESULTS: Both groups had significant reductions in rehospitalization rates and symptom levels and increased participation in treatment. Patients in multifamily group treatment had higher employment rates during the study. Otherwise, few significant differences in the major outcome variables were found. In both treatment conditions family members reported significant improvements in their objective and subjective burden; in friction, dissatisfaction, and overinvolvement with the patient; and in the patient's functioning.
CONCLUSIONS: The results suggest that systematic family involvement enhances the rehabilitation and family-related outcomes of assertive community treatment. Patients in multifamily group treatment had better employment outcomes.

Entities:  

Mesh:

Year:  1996        PMID: 8807689     DOI: 10.1176/ps.47.7.744

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  10 in total

Review 1.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Family interventions for mental disorders: efficacy and effectiveness.

Authors:  Ian R H Falloon
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

3.  Portland identification and early referral: a community-based system for identifying and treating youths at high risk of psychosis.

Authors:  William R McFarlane; William L Cook; Donna Downing; Mary B Verdi; Kristen A Woodberry; Anita Ruff
Journal:  Psychiatr Serv       Date:  2010-05       Impact factor: 3.084

Review 4.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Hanna Bergman; Mariam A Khokhar; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2017-01-06

5.  Assertive community treatment for people with severe mental illness: the effect on hospital use and costs.

Authors:  D Salkever; M E Domino; B J Burns; A B Santos; P A Deci; J Dias; H R Wagner; R A Faldowski; J Paolone
Journal:  Health Serv Res       Date:  1999-06       Impact factor: 3.402

6.  Family engagement as part of managing patients with mental illness in primary care.

Authors:  Hatta Santoso Ong; Paula Ann Fernandez; Hui Khim Lim
Journal:  Singapore Med J       Date:  2021-05       Impact factor: 1.858

Review 7.  Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.

Authors:  Ori Elis; Janelle M Caponigro; Ann M Kring
Journal:  Clin Psychol Rev       Date:  2013-07-16

Review 8.  Interventions for obtaining and maintaining employment in adults with severe mental illness, a network meta-analysis.

Authors:  Yvonne B Suijkerbuijk; Frederieke G Schaafsma; Joost C van Mechelen; Anneli Ojajärvi; Marc Corbière; Johannes R Anema
Journal:  Cochrane Database Syst Rev       Date:  2017-09-12

Review 9.  The burden of schizophrenia on caregivers: a review.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  Advances in interventions for families with a relative with a personality disorder diagnosis.

Authors:  Perry D Hoffman; Alan E Fruzzetti
Journal:  Curr Psychiatry Rep       Date:  2007-02       Impact factor: 8.081

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.